Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of pH-Responsive Ionisable Lipid Nanoparticles as Cisplatin Delivery Vehicles for Treating Cisplatin-Resistant Ovarian Cancer.

Pharmaceutics·2026
Same author

Identification and characterization of phyllochlorin sodium as a novel chlorin-derived photosensitiser.

Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology·2026
Same author

A Novel 3D High-Throughput Phenotypic Drug Screening Pipeline to Identify Drugs with Repurposing Potential for the Treatment of Ovarian Cancer.

Advanced healthcare materials·2025
Same author

Redefining success: a scientist's transition from researcher to research advisor.

Immunology and cell biology·2025
Same author

Leader cells promote immunosuppression to drive ovarian cancer progression in vivo.

Cell reports·2024
Same author

Leader Cells: Invade and Evade-The Frontline of Cancer Progression.

International journal of molecular sciences·2024
Same journal

Predicting Post-Radiotherapy Lymphocyte Recovery for Individualized Risk Stratification in Locally Advanced Esophageal Squamous Cell Carcinoma.

Current oncology (Toronto, Ont.)·2026
Same journal

From Adjunct to Essential: Integrating Supportive Care into Oncology.

Current oncology (Toronto, Ont.)·2026
Same journal

Next-Generation Sequencing in Differentiated Thyroid Cancer Patients Treated with Lenvatinib: Results and Challenges in Real-Life Practice.

Current oncology (Toronto, Ont.)·2026
Same journal

The Route of Administration Determines the Efficacy of Zinc in Preventing Radiation-Induced Oral Mucositis: A Systematic Review and Meta-Analysis.

Current oncology (Toronto, Ont.)·2026
Same journal

Mechanisms of Progression and Challenges for Intervention in the Natural History of Early Prostate Cancer: A Narrative Review.

Current oncology (Toronto, Ont.)·2026
Same journal

Maintenance Therapy in Acute Myeloid Leukemia: Current Perspectives and Future Directions.

Current oncology (Toronto, Ont.)·2026
See all related articles

Related Experiment Video

Updated: May 8, 2025

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

1.8K

Challenges in Implementing Comprehensive Precision Medicine Screening for Ovarian Cancer.

Laura R Moffitt1,2, Nazanin Karimnia1,2, Amy L Wilson1,2

  • 1Hudson Institute of Medical Research, Clayton 3168, Australia.

Current Oncology (Toronto, Ont.)
|December 27, 2024
PubMed
Summary
This summary is machine-generated.

Precision medicine offers targeted cancer treatments but faces challenges in ovarian cancer due to tumor diversity. Overcoming barriers like sample quality, standardized methods, and data management is crucial for improving patient outcomes.

Keywords:
epithelial ovarian cancergenomic screeninghigh-throughput drug screeningprecision medicinetumour heterogeneity

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.2K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.7K

Related Experiment Videos

Last Updated: May 8, 2025

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

1.8K
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.2K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.7K

Area of Science:

  • Oncology
  • Genomics
  • Translational Medicine

Background:

  • Precision medicine has transformed cancer care, yet its application in ovarian cancer is hindered by significant biological complexity.
  • Ovarian cancer's diverse tumor biology and heterogeneity complicate genetic profiling and the identification of treatment response biomarkers.

Purpose of the Study:

  • To review the multifaceted barriers impeding the implementation of precision medicine in ovarian cancer.
  • To explore ethical, socio-economic, and logistical challenges associated with precision oncology in this disease.

Main Methods:

  • Literature review and synthesis of current research on precision medicine in ovarian cancer.
  • Analysis of challenges in tissue acquisition, assay development, data infrastructure, and ethical considerations.

Main Results:

  • Key barriers include obtaining adequate tissue, standardizing screening assays, and managing complex data infrastructure.
  • Ethical issues concerning patient consent, data privacy, and health equity require careful navigation.

Conclusions:

  • Addressing socio-economic factors, enhancing patient and professional education, and developing supportive regulatory frameworks are vital.
  • Interdisciplinary collaboration is essential for advancing precision medicine and improving ovarian cancer patient care and outcomes.